利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.063 秒)

    Novel receptor-type phosphotyrosine phosphatase-alpha
    2.
    发明申请
    Novel receptor-type phosphotyrosine phosphatase-alpha 审中-公开
    新型受体型磷酸酪氨酸磷酸酶-α

    公开(公告)号：US20050032087A1

    公开(公告)日：2005-02-10

    申请号：US10777144

    申请日：2004-02-13

    申请人： Joseph Schlessinger ,  Jan Sap

    发明人： Joseph Schlessinger ,  Jan Sap

    IPC分类号： C07K14/705 ,  C12N9/16 ,  C12Q1/68 ,  C07H21/04

    CPC分类号： C07K14/705 ,  C07K2319/00 ,  C12N9/16

    摘要： A novel receptor-type protein tyrosine phosphatase (RPTP) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. Included in this family of proteins are human RPTPα, human RPTPβ and human RPTPγ. The RPTP protein or glycoprotein may be produced by recombinant means. Antibodies to the proteins, methods for measuring the quantity of the proteins, methods for screening compounds, such as drugs, which can bind to the proteins and inhibit or stimulate their activity, are provided.

    摘要翻译： 新型受体型蛋白酪氨酸磷酸酶（RPTP）蛋白或糖蛋白及其编码的DNA在多种哺乳动物组织中表达。 这种蛋白质家族包括人类RPTPα，人RPTPbeta和人类RPTPgamma。 可以通过重组方法产生RPTP蛋白或糖蛋白。 提供了对蛋白质的抗体，用于测量蛋白质量的方法，用于筛选可结合蛋白质并抑制或刺激其活性的化合物（例如药物）的方法。

    Methods and Compositions for Assessing and Treating Cancer
    4.
    发明申请
    Methods and Compositions for Assessing and Treating Cancer 审中-公开
    评估和治疗癌症的方法和组合

    公开(公告)号：US20130315934A1

    公开(公告)日：2013-11-28

    申请号：US13881623

    申请日：2011-10-28

    申请人： Ruth Halaban ,  Michael Krauthammer ,  Joseph Schlessinger ,  Titus J. Boggon

    发明人： Ruth Halaban ,  Michael Krauthammer ,  Joseph Schlessinger ,  Titus J. Boggon

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C07K14/4722 ,  C12N9/14 ,  G01N33/5743 ,  G01N2333/82 ,  G01N2800/52

    摘要： The invention relates to methods and compositions for identifying mutations associated with cancer, such as melanoma. More particularly, the invention relates to methods and compositions for assessing particular mutations as markers for cancer, such as melanoma. Such methods and compositions allow medical providers to diagnose cancer, such as melanoma, based upon the presence of one or more particular mutations in a subject, as compared with an otherwise healthy control. The methods and compositions are also useful in guiding the type of therapy to be applied, and monitoring the effects of the therapy applied.

    摘要翻译： 本发明涉及用于鉴定与癌症相关的突变的方法和组合物，例如黑素瘤。 更具体地，本发明涉及用于评估特定突变作为癌症标志物的方法和组合物，例如黑素瘤。 与其他健康对照相比，这样的方法和组合物允许医疗提供者基于受试者中一种或多种特定突变的存在来诊断癌症，例如黑素瘤。 方法和组合物也可用于指导所应用的治疗类型，并监测所施用的治疗效果。

    Methods for treatment or diagnosis of disease or disorders associated with an APB domain
    5.
    发明申请
    Methods for treatment or diagnosis of disease or disorders associated with an APB domain 审中-公开
    用于治疗或诊断与APB结构域相关的疾病或病症的方法

    公开(公告)号：US20050032689A1

    公开(公告)日：2005-02-10

    申请号：US10704128

    申请日：2003-11-10

    申请人： Benjamin Margolis ,  Joseph Schlessinger ,  Vijay Yajnik

    发明人： Benjamin Margolis ,  Joseph Schlessinger ,  Vijay Yajnik

    IPC分类号： A61K38/00 ,  C07K14/71 ,  G01N33/53

    CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention concerns methods for diagnosis and treatment of diseases or disorders characterized by abnormal cellular signal transduction involving a newly identified region, herein termed the “APB domain.” APB domain binding between proteins is believed to play an important role in signal transduction pathways and, thereby, influence cellular events. Thus, APB mediated activity plays a role in signal transduction pathways and agents modulating APB mediated activity can be used to treat diseases or disorders involving proteins containing APB domains.

    摘要翻译： 本发明涉及用于诊断和治疗特征在于涉及新鉴定区域的异常细胞信号转导的疾病或病症的方法，这里称为“APB结构域”。 认为蛋白质之间的APB结构域结合在信号转导途径中起重要作用，从而影响细胞事件。 因此，APB介导的活性在信号转导途径中起作用，并且调节APB介导的活性的试剂可用于治疗涉及含有APB结构域的蛋白质的疾病或病症。

    Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
    6.
    发明授权
    Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases 失效
    非胰岛素受体酪氨酸激酶酪氨酸激酶结构域的晶体

    公开(公告)号：US06682921B1

    公开(公告)日：2004-01-27

    申请号：US09664526

    申请日：2000-09-18

    申请人： Moosa Mohammadi ,  Joseph Schlessinger ,  Stevan R. Hubbard

    发明人： Moosa Mohammadi ,  Joseph Schlessinger ,  Stevan R. Hubbard

    IPC分类号： C12N912

    CPC分类号： G01N33/6842 ,  C07K14/71 ,  C12N9/1205 ,  G01N33/68

    摘要： Crystals of the tyrosine kinase domain of cytoplasmic tyrosine kinases and receptor tyrosine kinases that undergo ligand-mediated receptor dimerization are provided. In particular, crystals of a mutant of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FLGK), alone and in complex with a non-hydrolyzable adenosine triphosphate analogue, are provided. Also provided are the high resolution three dimensional structures of crystalline FLGK, both alone and in co-complex with the adenosine triphosphate analogue, as determined by X-ray diffraction.

    摘要翻译： 提供了经历配体介导的受体二聚化的细胞质酪氨酸激酶和受体酪氨酸激酶的酪氨酸激酶结构域的晶体。 特别地，提供单独的和与不可水解的三磷酸腺苷类似物复合的成纤维细胞生长因子受体1（FLGK）的酪氨酸激酶结构域的突变体的晶体。 还提供了通过X射线衍射测定的结晶FLGK的单分辨率和与三磷酸腺苷类似物的共配合物的高分辨率三维结构。

    Treatment or diagnosis of diseases or conditions associated with a BLM domain
    7.
    发明授权
    Treatment or diagnosis of diseases or conditions associated with a BLM domain 失效
    治疗或诊断与BLM结构域相关的疾病或病症

    公开(公告)号：US06045797A

    公开(公告)日：2000-04-04

    申请号：US866381

    申请日：1997-05-30

    申请人： Ben Lewis Margolis ,  Joseph Schlessinger

    发明人： Ben Lewis Margolis ,  Joseph Schlessinger

    IPC分类号： A61P43/00 ,  C07K14/475 ,  C07K14/485 ,  C07K14/71 ,  A61K39/00 ,  C07K1/00

    CPC分类号： C07K14/485 ,  C07K14/475 ,  C07K14/71

    摘要： A method for treatment of a disease or condition in an organism characterized by an abnormal level of interaction between a BLM domain and its natural binding partner is described. The disease or condition may also be characterized by an abnormality in a signal transduction pathway, wherein the pathway contains a protein with a BLM domain. The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complex formed between the BLM domain-containing protein and its natural binding partner. A method for diagnosis of such a disease or condition by detecting the level of such interaction as an indication of that disease or condition is also described. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described. The invention also features a peptide comprising, consisting or consisting essentially of a BLM domain.

    摘要翻译： 描述了用于治疗生物体中疾病或病症的方法，其特征在于BLM结构域与其天然结合配偶体之间的相互作用异常水平。 疾病或病症的特征还在于信号转导途径的异常，其中该途径含有具有BLM结构域的蛋白质。 该方法包括在体内破坏或促进相互作用（或信号）。 该方法还涉及抑制在含有BLM结构域的蛋白质与其天然结合配偶体之间形成的复合物的活性。 还描述了通过检测这种相互作用的水平来诊断这种疾病或病症的方法，作为该疾病或病症的指征。 此外，描述了通过测定潜在剂以破坏或促进该相互作用的能力来筛选可用于治疗这种疾病或病症的药剂的方法。 本发明还特征在于肽，其包含由BLM结构域组成或由其组成。

    Receptor-type phosphotyrosine phosphatase-alpha
    9.
    发明授权
    Receptor-type phosphotyrosine phosphatase-alpha 失效
    受体型磷酸酪氨酸磷酸酶-α

    公开(公告)号：US5888794A

    公开(公告)日：1999-03-30

    申请号：US448288

    申请日：1995-05-23

    申请人： Joseph Schlessinger ,  Jan M Sap

    发明人： Joseph Schlessinger ,  Jan M Sap

    IPC分类号： C07K14/705 ,  C12N9/16 ,  A61K38/46

    CPC分类号： C12N9/16 ,  C07K14/705 ,  C07K2319/00

    摘要： A novel receptor-type protein tyrosine phosphatase (RPTP) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. Included in this family of proteins are human RPTP.alpha., human RPTP.beta. and human RPTP.gamma.. The RPTP protein or glycoprotein may be produced by recombinant means. Antibodies to the proteins, methods for measuring the quantity of the proteins, methods for screening compounds, such as drugs, which can bind to the proteins and inhibit or stimulate their activity, are provided.

    摘要翻译： 新型受体型蛋白酪氨酸磷酸酶（RPTP）蛋白或糖蛋白及其编码的DNA在多种哺乳动物组织中表达。 蛋白家族包括人RPTPα，人RPTPβ和人类RPTPγ。 可以通过重组方法产生RPTP蛋白或糖蛋白。 提供了对蛋白质的抗体，用于测量蛋白质量的方法，用于筛选可结合蛋白质并抑制或刺激其活性的化合物（例如药物）的方法。